R&D at a glance

Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines, establishing our leadership position in key therapeutic areas, ensuring sustainable lifecycle management and, most importantly, creating a company of inspiring people throughout our R&D organization.

 

KEY FACTS

  • In 2017, we invested €266 million in R&D, equivalent to 14% of sales
  • We have 550 employees dedicated to R&D
  • Ipsen’s R&D activities are focused in Europe (France, UK, Ireland and Germany), the USA and China.
  • Our 3 main R&D hubs are located in Paris-Saclay, France; Oxford in the UK and Cambridge in the USA and we have 5 other R&D sites located in China, France, Germany, Ireland and the UK.
  • We have nine clinical studies in Phase III
  • In 2017, we achieved:
    • Seven new regulatory approvals
    • New laboratory building in Dreux
    • A £22 million investment at our campus at Wrexham, U.K.
    • 1st recombinant toxin ever to enter clinical development
    • Largest acquisition in Ipsen’s history

 

Alex-Lebeaut

Patients are always on our minds and inspire us to work faster and better. We empower our teams to take and manage risks to make timely decisions. We listen to feedback from patients, partners and collaborators to improve our performance.

Dr Alexandre Lebeaut, Executive Vice President Research & Development, Chief Scientific Officer.

 

 

NUMBER OF IPSEN SPONSORED CLINICAL STUDIES COMPLETED IN 2017

 

Therapeutic Area Study Phase # Studies Subjects
Oncology and Rare Diseases  I  1  4
Neuroscience  II  1  25
III 1 605
Consumer Healthcare  I  1  73
  • Home
  • R&D at a glance
  • Our R&D strategy
  • Pipeline
  • Clinical trials
  • Our R&D Specialisms
  • Our R&D Power Bases

    • Our R&D strategy

    As a global biopharmaceutical company, with a focus on innovation and specialty care, we have the ambition to build a robust, valuable and sustainable portfolio of innovative medicines to meet our patient’s needs. Our R&D strategy is guided by our end goal to ensure that we bring innovative medicines to market as quickly as possible to address unmet patient needs in the areas of Oncology, Neuroscience and Rare Diseases.

    Pipeline

    Ipsen’s R&D has a valuable pipeline encompassing both lifecycle management of our well-established products and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.

    Clinical Trials

    Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core areas of focus. A global network of healthcare professionals help us test new treatments and ensure their efficacy and safety by conducting studies called clinical trials.We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, as well as a proven ability to bring new, life changing therapies successfully through clinical development.

    Our R&D Specialisms

    Ipsen has a leading-edge technological platform in toxins, in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of strong external partnerships in the field. With their unique properties, toxin molecules offer potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine.

    Our R&D Power Bases

    We decided to locate our main R&D centres in world-class scientific hubs to take advantage of the networking opportunities and to progress our external innovation philosophy within established scientific ecosystems. Our three main sites are connected as an ‘innovation grid’, sharing real-time information, allowing us to adapt and focus capabilities to maximize our search and evaluation strategies on a global scale.